Biomarker ID 2537 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2537 |
| Biomarker | SLC38A2, AF116620, MYO1B, SULT2A1, PRRG1, FLJ14153, C8A, HSPB7, UBE2D3, AF143323, CTH, L08441, DSIPI, NYD-SP21, AFG3L1, HGD, LRP8, SDHD, ALPL, HPX, AK022053, AK027242, RFX5, GALNT10, KIAA1671, NFKBIB, LOC149832, UACA, GNG10, AL110138, AK026168, INHBA, LAMP1, MLL5, MLLT6, Z36876, BDG29, FLJ12800, ARN |
| Biomarker Name/Symbol (given in Publication) | 120 genes-signature ( SLC38A2, AF116620, MYO1B, SULT2A1, PRRG1, FLJ14153, C8A, HSPB7, UBE2D3, AF143323, CTH, L08441, DSIPI, NYD-SP21, AFG3L1, HGD, LRP8, SDHD, ALPL, HPX, AK022053, AK027242, RFX5, GALNT10, KIAA1671, NFKBIB, LOC149832, UACA, GNG10, AL110138, AK026168, INHBA, LAMP1, MLL5, MLLT6, Z36876, BDG29, FLJ12800, ARNT, HOXD9, TACR3, MCM2, AK021746, DKC1, BUB1, HNRPA1, L77582, GAPD, KIF4A, KCNIP1, MCM7, MGC16733, CSNK2A1, UBE2C, RANBP1, ATF1, NONO, GAPD, GAPD, FLJ20736, FDX1, AL359568, ANGPTL3, APOC4, USP20, DAO, SIPL, SV2A, SCP2, AL110150, HAGH, FLJ20950, TGM5, INSIG1, FLJ10851, ZNF202, dJ222E13.1, PROZ, KIAA0102, RODH-4, S81578, EPHA3, HSPC230, EPB41L3, SLC34A1, GNAS, RHPN2, TXNL2, FLJ12618, KIAA0877, AGRN, EIF4E, FLT3LG, PIF1, GEMIN4, LIPC, NDUFB8, DKFZp586G0123, L37695, KIAA0435, FLJ20373, MPZL1, CSNK2A1, FACL3, ADAM29, AK001814, UBAP2, AEBP2, C40, PRKWNK1, SNRPA1, AB032959, POMC, TRIM28, GPC3, LOC56902, JRKL, PPP1CC, UMPK, DKC1) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Biomarker for early detection of liver cancer and validated on independent dataset |
| Experimental Condition | Edmondson grade 1 HCC v/s Edmondson grade 2/3 HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Discriminating among late-stage sample (between G1, G2 and G3) |
| Level of significance | p < 0.001 |
| Source | Tissue |
| PMID | 16175600 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | Training dataset:42 Primary HCCs,:30 HCCs (10 G1 [Edmondson grade 1 ], 10 G2 [Edmondson grade 2], and 10 G3 [Edmondson grade 13]), 10 LGDNs, and 10 HGDNs [premalignant lesions or dysplastic nodules of HCC] ; validation dataset : 14 samples (5 new samples and the 9 samples excluded from study) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | 91% |
| AUC | NA |
| Disease | Edmondson grade 1 HCC v/s Edmondson grade 2/3 HCC |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |